Viridian Therapeutics, Inc. (NASDAQ:VRDN) is Vivo Capital LLC's 9th Largest Position

Vivo Capital LLC reduced its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 41.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 982,576 shares of the company's stock after selling 695,631 shares during the period. Viridian Therapeutics accounts for about 2.1% of Vivo Capital LLC's holdings, making the stock its 9th biggest position. Vivo Capital LLC owned approximately 1.24% of Viridian Therapeutics worth $18,836,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Lord Abbett & CO. LLC purchased a new position in shares of Viridian Therapeutics in the third quarter valued at $8,917,000. JPMorgan Chase & Co. lifted its holdings in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock worth $9,108,000 after acquiring an additional 274,641 shares during the last quarter. Barclays PLC grew its position in Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after acquiring an additional 66,550 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Viridian Therapeutics by 1,603.4% during the third quarter. Principal Financial Group Inc. now owns 172,810 shares of the company's stock worth $3,931,000 after purchasing an additional 162,665 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after buying an additional 14,644 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts recently issued reports on VRDN shares. Needham & Company LLC restated a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock traded down $0.06 during trading on Friday, reaching $13.50. 524,676 shares of the stock traded hands, compared to its average volume of 1,199,501. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The business has a fifty day simple moving average of $14.28 and a two-hundred day simple moving average of $18.34.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.